Filing Details

Accession Number:
0001567619-18-002677
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-14 18:17:15
Reporting Period:
2018-09-12
Accepted Time:
2018-09-14 18:17:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1581720 Loxo Oncology Inc. LOXO Pharmaceutical Preparations (2834) 462996673
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1612312 H. Joshua Bilenker C/O Loxo Oncology, Inc.
One Landmark Square, Suite 1122
Stamford CT 06901
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-12 10,000 $1.18 145,407 No 4 M Direct
Common Stock Disposition 2018-09-12 700 $164.16 144,707 No 4 S Direct
Common Stock Disposition 2018-09-12 3,700 $165.18 141,007 No 4 S Direct
Common Stock Disposition 2018-09-12 2,400 $166.49 138,607 No 4 S Direct
Common Stock Disposition 2018-09-12 1,800 $167.38 136,807 No 4 S Direct
Common Stock Disposition 2018-09-12 800 $168.51 136,007 No 4 S Direct
Common Stock Disposition 2018-09-12 200 $169.89 135,807 No 4 S Direct
Common Stock Disposition 2018-09-12 400 $171.08 135,407 No 4 S Direct
Common Stock Acquisiton 2018-09-13 7,473 $1.18 142,880 No 4 M Direct
Common Stock Acquisiton 2018-09-13 2,527 $3.65 145,407 No 4 M Direct
Common Stock Disposition 2018-09-13 5,636 $165.43 139,771 No 4 S Direct
Common Stock Disposition 2018-09-13 3,402 $166.52 136,369 No 4 S Direct
Common Stock Disposition 2018-09-13 962 $167.32 135,407 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-09-12 10,000 $0.00 10,000 $1.18
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-09-13 7,473 $0.00 7,473 $1.18
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-09-13 2,527 $0.00 2,527 $3.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
63,932 2023-11-14 No 4 M Direct
56,459 2023-11-14 No 4 M Direct
92,985 2024-06-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 30,000 Indirect By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  2. Represents the aggregate of sales effected on the same day at different prices.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.75 to $164.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.75 to $165.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.04 to $168.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.06 to $169.0599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.48 to $170.4799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.68 to $171.6799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.02 to $166.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.18 to $168.1799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  13. The options have fully vested and are immediately exercisable.
  14. The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.